Abstrait
Le cancer de l’ovaire touche souvent la femme âgée: il atteint la femme de moins de 45 ans dans environ 15 % des cas, de 45 à 65 ans dans 40 % des cas et après 65 ans dans 45 % des cas (8). Le nombre de nouveaux cas de cancer de l’ovaire est estimé pour la France, en 2000, à 4 488, représentant ainsi 3,8 % des cancers féminins. Le cancer de l’ovaire est responsable de 3 508 décès pour cette même année, soit un peu plus de 6 % des décès féminins par cancer (34). La probabilité pour une femme française d’avoir un cancer de l’ovaire au cours de sa vie est évaluée à 1,3 %. Les taux d’incidence spécifiques augmentent avec l’âge jusqu’à 65 ans pour l’incidence et d’une façon constante jusqu’aux âges les plus avancés pour la mortalité. Le cancer de l’ovaire est un cancer dont l’incidence serait en diminution depuis 1980, passant d’un taux d’incidence de 11,9 pour 100 000 femmes en 1980, à 9 en 2000 (34). Le taux de mortalité standardisé est de 5,4. Le cancer de l’ovaire partage certains facteurs de risque avec le cancer du sein, excepté la contraception orale qui aurait un effet protecteur dans la survenue d’un cancer ovarien.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Références
Anderson M, Storm H, Mouridsen H (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–17
Annual Report. Petterson F, Creasman WT, Shephard JH, Pecorelli S (1995) International Federation of Gynecology and Oncology, eds. Annual report on the results of treatment in gynecological cancer. Stockholm, Sweden: Editorial Office, Radiumhemmet
Baldwin JG (1988) Hematopoietic function in the elderly. Arch Intern Med 148: 2544–6
Brinton LA, Hamman RF, Huggins GR et al. (1987) Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 79: 23–30
Burke TW, Eiffel PJ, Muggia FM (1997) Cancer of the uterine body. In: Vita VT, Hellman S, Rosenberg SA. Cancer principles and practice of oncology. Philadelphia. Lippincott, Raven: 1478–502
Calais G, Vitu L, Descamps P et al. (1990) Preoperative or postoperative brachytherapy for patients with endometrial carcinoma stage I and II. Int J Radiat Oncol Biol Phys 19: 523.
Edmonson JH, Su J, Crook JE (1993) Treatment of ovarian cancer in elderly women. Cancer 71: 615–17
Feuilhade F (1996) Le cancer de l’ovaire de la femme âgée. Cahier d’oncologie 5: 8–15
Fisher B, Costantino J, Redmond C, Fisher E, Wickerham L, Cronin W (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–37
Fornander T, Rutqvist L, Cedermark B et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117–20
Freyer G, Weber B, Mousseau M et al. (2000) Multidimensional geriatric assessment (MGA) predicts feasibility of standart carboplatin (CB)-Cyclophospha-mide (CY) in women over 70 with advanced ovarian carcinoma (AOC): A GYNECO study. Proceedings of ASCO
Gerbaulet A, Horiot JC (1992) Généralités sur les traitements des cancers gynécologiques. In: Bourgeois JP, Chavaudra J, Eschwege F. Radiothérape oncologique, Paris, Hermann 270–80
Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB (1994) Treatment tolerance of elderly cancer patients entered into phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol 12: 2447–52
Gloeckler Ries LA (1993) Ovarian cancer: survival and treatment differences by age. Cancer 71: 524–9
Grady D, Gebretsadik T, Kerlikowske K et al. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304–13
Higginson J, Muir CS, Munoz N (1992) Human cancer: epidemiology and environnemental causes. Cambridge University Press. Cambridge 1–577
Hill C, Doyon F, Sancho-Garnier H (1997) Fr pidémiologie des cancers. Flammarion Paris: 53–6
Kalandidi A, Tzonou A, Lipworth L et al. (1996) A case-control study of endometrial cancer in relation to reproductive, somatometric and life-style variables. Oncology 53: 354–9
Kirova Y, Calitchi E, Feuilhade F (2001) Les cancers de l’ovaire et l’uterus chez la femme âgée. Oncologie 3: 94–9
Kolysko-Tuxen M, Lund B, Paaske O et al. (1993) Second look laparotomy in the management of patients after radical surgery for ovarian cancer. Ann Oncol 3: 169–71
La Vecchia C, Decarli A, Fasoli M, Gentile A (1986) Nutrition and diet in the etiology of endometrial cancer. Cancer 57: 1248–53
La Vecchia C, Franceschi S, Decarli A et al. (1984) Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 73: 667–71
Levi F, La Vecchia C, Negri E et al. (1992) Body mass at different ages and subsequent andometial cancer risk. Int J Cancer 50: 567–71
Markman M, Lewis JL, Saigo P et al. (1993) Epithelial ovarian cancer in the elderly: Memorial Sloan Kettering Cancer Center experience. Cancer 71: 634–7
Moradi T, Nyren O, Bergstrom R et al. (1998) Risk for endometrial cancer in relation to accupational physical ativity: a nationwide cohort study in Sweden. Int J Cancer 76: 665–70
NIH Consensus Statement (1994) Ovarian Cancer: screening, treatment and follow-up. 12: 1–30
Onetto N, Canetta R, Winograd B et al. (1993) Overview of taxol safety. A workshop on taxol and taxus. Monographs of the National Cancer Institute 15: 131–40
Orth G, Croissant O (1988) Papillomavirus humans et cancer. Bull Inst Pasteur 86: 297–315
Parazzini F, La Vecchia C, Bocciolone L, Franceschi S (1991) The epidemiology of endometrial cancer. Gynecol Oncol 41: 1–16
Potiscman N, Swanson CA, Brinton LA et al. (1993) Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control 4: 239–50
Raverdy N (2000) Le cancer de l’ovaire. Incidence du cancer en France. Estimations régionales 1985–1995; pp 28
Ribeiro G, Swindell R (1992) The Christie Hospital adjuvant tamoxifen trial. NCI Monogr 11: 121–5
Rose PG0 (1996) Endometrial carcinoma. N Engl J Med 335: 640–49
Remontet L, Buemi A, Velten M et al. Evolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000. Edition de l’Institut de veille sanitaire
Stewart H (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer: Scottish Cancer Trials Breast Group. NCI Monogr 11: 117–20
Thyss A, Saudes L, Otto J et al. (1994) Renal tolerance of cisplatine in patients more than 80 years old. J Clin Oncol 12: 2121–5
Ursin G, Peters RK, Henderson BE et al. (1994) Oral contraceptive use and adenocarcinoma of cervix. Lancet 344: 1390–94
Van der Burg MEL, Van Lent M, Buise M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–34
Zaheer W, Lichtman SM, De Marco L et al. (1994) The use of taxol in elderly patients. Proceedings of ASCO 13: 1518
Vasey PA, Jayson GC, Gordon A et al. (2004) Phase III Randomized trial of Docetaxel-Carboplatin vs Paclitaxel-Carboplatin as first line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682–91
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag France
About this chapter
Cite this chapter
Kirova, Y., Calitchi, E., Feuilhade, F. (2007). Tumeurs gynécologiques. In: Morère, JF., Rainfray, M. (eds) Cancer du sujet âgé. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-48618-0_9
Download citation
DOI: https://doi.org/10.1007/978-2-287-48618-0_9
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-25209-9
Online ISBN: 978-2-287-48618-0